Alexion Pharmaceuticals (ALXN) Stock Research, Analysis & News
Quick Analysis on Alexion Pharmaceuticals (ALXN) Stock as of May 18, 2012
 | Previous Closing Price $84.35 is below its 50 day moving average $89.62 |
 | Previous Closing Price $84.35 is above 200 day moving average of $78.88 |
| The Price/Earnings To Growth ratio (PEG) is great than 1 |
 | The Stock pays no dividend |
| The closing price $84.35 is less than 14.74% away from its one year target price of $96.78 |
 | Current Short Ratio 2.80 is great than 1 |
(See more information about Alexion Pharmaceuticals (ALXN) Stock below)
Alexion Pharmaceuticals (ALXN) Stock Profile Summary
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. It focuses on products for severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases; transplant rejection; cancer; and autoimmune disorders. The company markets Soliris (eculizumab) for the treatment of patients with paroxysmal nocturnal hemoglobinuria, a blood disorder. It also conducts various Phase II clinical trials on Soliris for the treatment of atypical hemolytic uremic syndrome, MPGN II dense deposit disease, presensitized renal transplant, myasthenia gravis, neuromyelitis optica, multifocal motor neuropathy, and dry age-related macular degeneration. In addition, the company conducts preclinical studies on Soliris for the treatment of presensitized cardiac transplant, cold agglutinin disease, and catastrophic antiphospholipid syndrome. Further, its clinical programs include Samalizumab, which is in Phase I/II clinical trials for the treatment of chronic lymphocytic leukemia and multiple myeloma. Alexion Pharmaceuticals serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company was founded in 1992 and is headquartered in Cheshire, Connecticut.
Alexion Pharmaceuticals (ALXN) Stock Key Statistics Research and Analysis as of May 18, 2012
| Stock Exchange | NasdaqNM |
| Market Capitalization | $15.750B
|
| Trade Volume (Average Trading Volume) | 1,746,223 (1,239,760) |
| Price/Sales | 18.29 |
| Price/Book | 12.99 |
| P/E | 84.18 |
| Earning/Share | $1.002 |
| Current Year EPS Estimate | $1.79 |
| Next Year EPS Estimate | $2.54 |
| Previous Closing Price | $84.35 |
| 50 Day Price Moving Average | $89.62 |
| 200 Day Price Moving Average | $78.88 |
| 1 yr Target Price | $96.78 |
| PEG Ratio | 1.38 |
| Short Ratio | 2.80 |
| EBITDA | $293.1M |
Alexion Pharmaceuticals (ALXN) Stock Competitor Research and Analysis
Mutual Funds with Alexion Pharmaceuticals (ALXN) Stock in its top 10 holdings
ETFs with Alexion Pharmaceuticals (ALXN) Stock in its top 10 holdings
Stock Research on Alexion Pharmaceuticals (ALXN)
Latest Market News on Alexion Pharmaceuticals (ALXN)
Click here to find the latest news on Alexion Pharmaceuticals (ALXN)
Looking for Market Opportunties?
Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center
Research on Alexion Pharmaceuticals (ALXN)
